All compounds sold on this site are research-grade materials intended exclusively for in-vitro laboratory research by qualified professionals.
A dual-incretin research peptide — a GIP and GLP-1 receptor co-agonist studied in metabolic and glucose-regulation models.
Published preclinical literature has examined TZ-GLP’s effects on insulin signaling, appetite pathways, and energy balance.
Identity
TZ-GLP 10 mg · CAS 2023788-19-2
39-amino-acid GIP / GLP-1 co-agonist
≥99% HPLC · 3 mL vial
TZ-GLP is a synthetic 39-amino-acid peptide engineered to activate the GIP and GLP-1 receptors simultaneously (a dual incretin agonist). Published preclinical literature has examined its effects on insulin secretion, glucose handling, appetite signaling, and body-weight endpoints in metabolic models.
Reconstitution & storage
Common research protocol — 2 mL bacteriostatic water yields a working solution for laboratory use. Lyophilised: store at 2–8 °C, protected from light; refer to the lot CoA for expiration. Reconstituted: refrigerate at 2–8 °C; long-term storage at −20 °C per laboratory protocol.
Documentation — batch Certificate of Analysis (HPLC, third-party) provided for the lot shipped.
For Research Use Only. Not for Human or Veterinary Use. Not a drug, food, or supplement; not evaluated by the FDA; not intended for human or animal use.
TESTED · 99.87%
